Current European Non-Compliance Report for an Indian API Manufacturer
Recommendation
Thursday, 29 October 2026 9 .00 - 14.00 h
Practical Approaches for Assessing the Risks of Impurities
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Major deficiencies observed during GMP inspections are entered into the EudraGMDP database. There, you can find a current Non-Compliance Report issued by the Italian Medicines Agency for the Indian API manufacturer Krebs Biochemicals & Industries Ltd.
The Non-Compliance Report covers the manufacture of the API Simvastatin, whereby not only the chemical synthesis but also the further processing of the API as well as the quality control are affected.
In total, 24 deficiencies were observed. Among them, five were classified as major but without further details:
- Deviation
- Personnel training
- Facilities
- Finish product storage management
- Production and monitoring of purified water
From the Authority's point of view, the combination of the findings and the weaknesses of the quality management system presented an intolerable risk to public health. Now, it is recommended that the national competent authorities evaluate on the basis of risk whether a recall of the medicinal products using the APIs concerned is necessary or not. It is also recommended to prohibit the supply of the API and to suspend the CEP (Certificate of Suitability of Monographs of the European Pharmacopoeia).
Source: EudraGMDP database
Related GMP News
26.10.2026EMA and CMDh Expand List of Nitrosamine Limits
20.10.2026IPEC Publishes Version 3 of the Excipient Composition Guide
14.10.2026EMA Reports inconsistent Progress in International API Inspection Cooperation
23.09.2026FDA Warning Letter: serious GMP Deficiencies at a Chinese API Manufacturer
16.09.2026PFAS restriction: Commission highlights Importance of critical Medical Applications